The innovative pharmaceutical company invested by China Resources has been placed on the “blacklist” of centralized procurement.

On September 7, 2026, the National Healthcare Security Administration issued a notice placing the innovative pharmaceutical company under Huanru Investment on the “blacklist” of national organized drug procurement. This list aims to regulate the order of drug procurement. Companies on the list will be unable to participate in subsequent procurement projects, and their products will be directly affected in public hospital procurement channels. The reason for this penalty is that the company’s products did not pass the consistency evaluation.